J. Am. Acad. Dermatol. 2020 Jan 30
Outcome And Clinico-Phenotypical Features Of Acute Lymphoblastic Leukemia/Lymphoma With Cutaneous Involvement: A Multicentric Case-Series.
Bontoux C, De Masson A, Boccara O, Bodemer C, Fraitag S, Balme B, Franck N, Carlotti A, Comoz F, Verneuil L, Brasme JF, Duplan M, Croué A, Templier I, Beltraminelli H, Dereure O, Szablewski V, Thevenin C, Boulinguez S, Viraben R, Tournier E, Lamant L, Ortonne N, Ingen-Housz-Oro S, Beckerich F, Grange F, Durlach A, Amatore F, Frouin E, McIntyre E, Asnafi V, Kim R, Clappier E, Soulier J, Boissel N, Dombret H, Bagot M, Battistella M
Read More
Source: PubMed
Exp. Hematol. 2020 Jan 29
The effects of chemotherapy agents used to treat pediatric acute lymphoblastic leukemia patients on bone parameters and longitudinal growth of juvenile mice.
Straszkowski L, Jovic T, Castillo-Tandazo W, Ritchie DS, Purton LE
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Therapies for pediatric ALL have improved such that more than 80% of patients ...
Read More
Source: PubMed
Clin. Exp. Med. 2020 Jan 31
Prognostic significance of serum progranulin level in de novo adult acute lymphoblastic leukemia patients.
El-Ghammaz AMS, Azzazi MO, Mostafa N, Hegab HM, Mahmoud AA
Increased expression of progranulin (PGRN) has been reported in some hematological cancers, but limited information regarding its significance in acut ...
Read More
Source: PubMed
Bone Marrow Transplant. 2020 Jan 31
CD19/CD22 chimeric antigen receptor T-cell therapy for refractory acute B-cell lymphoblastic leukemia with FLT3-ITD mutations.
Jin A, Feng J, Wei G, Wu W, Yang L, Xu H, Zhang Y, Cui J, Chang AH, Hu Y, Huang H
Treatment of acute lymphoblastic leukemia (ALL) is still a challenge despite years of researching, especially for those of poor prognosis. Zhang and h ...
Read More
Source: PubMed
Adv Pharm Bull
Emerging Effects of Sepantronium Bromide (YM155) on MOLT-4 Cell Line Apoptosis Induction and Expression of Critical Genes Involved in Apoptotic Pathways.
Shojaei Moghadam K, Farshdousti Hagh M, Alivand MR, Fardi M, Movassaghpour AA, Mohammadi A, Moghadasi M, Solali S
Purpose: Sepantronium bromide (YM155) is a Survivin inhibitor which recently advanced as an anticancer agent in phase II clinical trials. Survivin bel ...
Read More
Source: PubMed
